- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05663489
Neurobiological Markers of Treatment Response for Anxiety and OCD
Study Overview
Status
Intervention / Treatment
Detailed Description
The primary study will include 500 OCD patients who will receive the B4DT. Symptom severity will be prospectively measured before treatment, approximately 10 days after treatment and three months after treatment. Saliva samples will be collected for later extraction of DNA methylation during the first day of treatment, the last day of treatment, and three months after treatment. A substudy will use multimodal magnetic resonance imaging (MRI) before treatment, approximately 10 days after treatment and three months after treatment. The substudy will also 100 patients with social anxiety disorder or panic disorder for DNA methylation and MRI, as well as 50 healthy controls for MRI. Clinical data will be collected from a consent-based quality register ("Kvalitetsregister for konsentrerte behandlingsformat").
The aim of the study is to investigate changes in DNA methylation as well as functional and structural brain networks that occur in patients undergoing B4DT, and to correlate these changes with immediate and long-term response to treatment.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Bjarne Hansen, PhD
- Phone Number: +4792090765
- Email: bjarne.kristian.aaslie.hansen@helse-bergen.no
Study Locations
-
-
Vestland
-
Bergen, Vestland, Norway, 5009
- Recruiting
- Bergen Center for Brain Plasticity
-
Contact:
- Bjarne Hansen, PhD
- Phone Number: +4792090765
- Email: bjarne.kristian.aaslie.hansen@helse-bergen.no
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosed with obsessive-compulsive disorder, panic disorder or social anxiety disorder using DSM-5 criteria
- Referred to National Clinic for 4-Day Treatment, Haukeland University Hospital, Bergen, Norway
- Consented to participate in the "Kvalitetsregister for konsentrerte behandlingsformat"
Exclusion Criteria:
- Suicidal, ongoing mania, primary eating disorder, intellectual disability, ongoing psychosis, ongoing substance abuse
For MRI substudy:
Inclusion Criteria:
- For the healthy controls, no previous or current psychiatric disorders as detected by the Mini International Neuropsychiatric Interview (MINI)
Exclusion Criteria:
- MRI incompatibility (e.g. pregnancy, metal implants)
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with obsessive-compulsive, social anxiety or panic disorder
Patients with obsessive-compulsive disorder.
The MRI substudy will also include patients with social anxiety or panic disorder
|
A concentrated and exposure-based psychological treatment over four consecutive days
|
For MRI substudy: Healthy controls
Healthy controls demographically matched to the patient group on age, sex and years of education
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time Frame: Before treatment
|
Symptom severity of obsessive-compulsive disorder
|
Before treatment
|
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time Frame: approximately 10 days after treatment
|
Symptom severity of obsessive-compulsive disorder
|
approximately 10 days after treatment
|
Yale-Brown Obsessive Compulsive Scale (Y-BOCS)
Time Frame: three months after treatment
|
Symptom severity of obsessive-compulsive disorder
|
three months after treatment
|
Panic Disorder Severity Scale (PDSS)
Time Frame: Before treatment
|
Symptom severity of panic disorder
|
Before treatment
|
Panic Disorder Severity Scale (PDSS)
Time Frame: approximately 10 days after treatment
|
Symptom severity of panic disorder
|
approximately 10 days after treatment
|
Panic Disorder Severity Scale (PDSS)
Time Frame: three months after treatment
|
Symptom severity of panic disorder
|
three months after treatment
|
Liebowitz Social Anxiety Scale (LSAS)
Time Frame: Before treatment
|
Symptom severity of social anxiety disorder
|
Before treatment
|
Liebowitz Social Anxiety Scale (LSAS)
Time Frame: approximately 10 days after treatment
|
Symptom severity of social anxiety disorder
|
approximately 10 days after treatment
|
Liebowitz Social Anxiety Scale (LSAS)
Time Frame: three months after treatment
|
Symptom severity of social anxiety disorder
|
three months after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DNA Methylation
Time Frame: Before treatment
|
Samples of saliva will be collected for genome-wide methylation and profiling will be carried out using the Illumina Infinium MethylationEPIC BeadChip system
|
Before treatment
|
DNA Methylation
Time Frame: approximately 10 days after treatment
|
Samples of saliva will be collected for genome-wide methylation and profiling will be carried out using the Illumina Infinium MethylationEPIC BeadChip system
|
approximately 10 days after treatment
|
DNA Methylation
Time Frame: three months after treatment
|
Samples of saliva will be collected for genome-wide methylation and profiling will be carried out using the Illumina Infinium MethylationEPIC BeadChip system
|
three months after treatment
|
Magnetic Resonance Imaging
Time Frame: Before treatment
|
Brain functional and structural MRI will be collected for a subset of 100 OCD and 100 anxiety disorder patients as well as 50 healthy controls
|
Before treatment
|
Magnetic Resonance Imaging
Time Frame: approximately 10 days after treatment
|
Brain functional and structural MRI will be collected for a subset of 100 OCD and 100 anxiety disorder patients as well as 50 healthy controls
|
approximately 10 days after treatment
|
Magnetic Resonance Imaging
Time Frame: three months after treatment
|
Brain functional and structural MRI will be collected for a subset of 100 OCD and 100 anxiety disorder patients as well as 50 healthy controls
|
three months after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bjarne Hansen, PhD, Haukeland University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BCBP-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on Bergen 4-Day Treatment (B4DT)
-
Karolinska InstitutetHelse-Bergen HFRecruitingObsessive-Compulsive DisorderSweden
-
Haukeland University HospitalUniversity of BergenRecruiting
-
BayerCompleted
-
The Royal Bournemouth HospitalCompletedArthroplasty, Replacement, Hip | Hip Replacement, TotalUnited Kingdom
-
TCM Biotech International Corp.Recruiting
-
Nihon Pharmaceutical Co., LtdCompleted
-
Brigham and Women's HospitalWeill Medical College of Cornell University; University of California, Davis; Florida International University and other collaboratorsCompletedHIV/AIDS | TuberculosisHaiti
-
Icahn School of Medicine at Mount SinaiU.S. Department of EducationCompletedTraumatic Brain InjuryUnited States
-
MorphoSys AGClinigen Healthcare LtdApproved for marketing
-
Kyowa Kirin Korea Co., Ltd.RecruitingHyperphosphatemiaKorea, Republic of